Lorenzo Galluzzi

Lorenzo Galluzzi (born 1980) is an Italian and French cell biologist best known for his experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology.

Biography

Galluzzi (born September 26, 1980) is currently Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College (New York, USA), and Honorary Associate Professor at the Faculty of Medicine of the Paris Descartes University (Paris, France).[1] Prior to joining Weill Cornell Medical College (2017), Galluzzi was a Junior Scientist of the Research Team "Apoptosis, Cancer and Immunity" at the Cordeliers Research Center (Paris, France; 2012-2016) under the direction of Dr. Guido Kroemer. Galluzzi did his post-doctoral training at the Gustave Roussy Cancer Center (Villejuif, France; 2009-2011), after receiving his PhD from the Paris Sud University (Le Kremlin-Bicetre, France; 2005-2008). Galluzzi is Associate Director of the European Academy for Tumor Immunology (EATI), and Founding Member of the European Research Institute for Integrated Cellular Pathology (ERI-ICP).[2]

Galluzzi is best known for his experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology.[1] In particular, he provided profound insights into the links between adaptive stress responses in cancer cells and the activation of a clinically relevant tumor-targeting immune response in the context of chemotherapy and radiation therapy.[3][4][5][6] As of today, Galluzzi has published more than 330 scientific articles in more than 80 different international peer-reviewed journals, collaborating with more than 3,000 co-authors.[7] According to Google Scholar, Galluzzi has a h-index of 85,[8] placing him amongst the top-50 Italian scientists working in biomedical sciences.[9] According to a survey published by Lab Times, he is currently the 6th and the youngest of the 30 most-cited European cell biologists (relative to the period 2007–2013).[10]

In addition to his research and dissemination activity, Galluzzi currently operates as Editor-in-Chief of three journals: OncoImmunology (which he co-founded with Dr. Guido Kroemer and Dr. Laurence Zitvogel in 2011),[11] International Review of Cell and Molecular Biology,[12] and Molecular and Cellular Oncology (which he co-founded with Dr. Guido Kroemer in 2013).[13] Galluzzi also serves as Section Chief Editor for Oncotarget (Autophagy and Cell Death section),[14] Founding Editor for Microbial Cell and Cell Stress,[15] and Associate Editor for Cell Death and Disease.[16]

References

  1. 1 2 Weill Cornell Medical College - People Retrieved July 19, 2017
  2. ↑ European Academy for Tumor Immunology - Official Website Retrieved July 19, 2017
  3. ↑ Galluzzi et al. Pharmacological modulation of autophagy: Therapeutic potential and persisting obstacles Retrieved July 19, 2017
  4. ↑ Galluzzi et al. Molecular definitions of autophagy and related processes Retrieved July 19, 2017
  5. ↑ Galluzzi et al. Immunogenic cell death in cancer and infectious disease Retrieved July 19, 2017
  6. ↑ Galluzzi et al. Essential versus accessory aspects of cell death: recommendations of the NCCD 2015 Retrieved July 19, 2017
  7. ↑ Profile on ResearchGate Retrieved July 19, 2017
  8. ↑ Profile on Google Scholar Retrieved July 26, 2017
  9. ↑ Top Italian Scientists Biomedical Sciences Retrieved July 26, 2017
  10. ↑ Publication Statistics: Cell Biology Retrieved July 19, 2017
  11. ↑ OncoImmunology - Editorial Board Retrieved July 19, 2017
  12. ↑ International Review of Cell and Molecular Biology - Homepage Retrieved July 19, 2017
  13. ↑ Molecular and Cellular Oncology - Editorial Board Retrieved July 19, 2017
  14. ↑ Oncotarget Autophagy and Cell Death - Homepage Retrieved July 19, 2017
  15. ↑ Microbial Cell - Editorial Board Retrieved July 19, 2017
  16. ↑ Cell Death and Disease - About the Editors Retrieved July 19, 2017

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.